MedTrace Logo

Granisetron Versus Pethidine in Treatment of Post Spinal Shivering in Cesarean Sections

NCT06513806 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2025-10-02

No results posted yet for this study

Summary

Granisetron Versus Pethidine in Treatment of Post Spinal Shivering in Cesarean Sections

Conditions

  • Anesthesia; Adverse Effect, Spinal and Epidural

Interventions

DRUG

Granisetron 1 Mg/mL Intravenous Solution

will receive granisetron 3 mg iv bolus

DRUG

Pethidin

will receive pethidine 25 mg iv bolus

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Ayman M Kamaly, MD · Ain Shams University

  • David S Said, Msc · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2024-09-25
Completion
2024-09-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06513806 on ClinicalTrials.gov